JP6940916B2 - フラジェリン組成物および使用 - Google Patents

フラジェリン組成物および使用 Download PDF

Info

Publication number
JP6940916B2
JP6940916B2 JP2017504404A JP2017504404A JP6940916B2 JP 6940916 B2 JP6940916 B2 JP 6940916B2 JP 2017504404 A JP2017504404 A JP 2017504404A JP 2017504404 A JP2017504404 A JP 2017504404A JP 6940916 B2 JP6940916 B2 JP 6940916B2
Authority
JP
Japan
Prior art keywords
flagellin
cancer
hours
cblb502
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017504404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523184A (ja
JP2017523184A5 (cg-RX-API-DMAC7.html
Inventor
メット，バディム
Original Assignee
ゲノム プロテクション，インコーポレイテッド
ゲノム プロテクション，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゲノム プロテクション，インコーポレイテッド, ゲノム プロテクション，インコーポレイテッド filed Critical ゲノム プロテクション，インコーポレイテッド
Publication of JP2017523184A publication Critical patent/JP2017523184A/ja
Publication of JP2017523184A5 publication Critical patent/JP2017523184A5/ja
Priority to JP2021142801A priority Critical patent/JP2021191781A/ja
Application granted granted Critical
Publication of JP6940916B2 publication Critical patent/JP6940916B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017504404A 2014-07-30 2015-07-29 フラジェリン組成物および使用 Expired - Fee Related JP6940916B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021142801A JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462031116P 2014-07-30 2014-07-30
US62/031,116 2014-07-30
US201562110744P 2015-02-02 2015-02-02
US62/110,744 2015-02-02
US201562117366P 2015-02-17 2015-02-17
US62/117,366 2015-02-17
PCT/US2015/042684 WO2016019034A1 (en) 2014-07-30 2015-07-29 Flagellin compositons and uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021142801A Division JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Publications (3)

Publication Number Publication Date
JP2017523184A JP2017523184A (ja) 2017-08-17
JP2017523184A5 JP2017523184A5 (cg-RX-API-DMAC7.html) 2021-01-07
JP6940916B2 true JP6940916B2 (ja) 2021-09-29

Family

ID=55218277

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017504404A Expired - Fee Related JP6940916B2 (ja) 2014-07-30 2015-07-29 フラジェリン組成物および使用
JP2017504354A Expired - Fee Related JP6646039B2 (ja) 2014-07-30 2015-07-30 フラジェリンベースの薬剤および効果的なワクチン接種を含めた使用
JP2021142801A Pending JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017504354A Expired - Fee Related JP6646039B2 (ja) 2014-07-30 2015-07-30 フラジェリンベースの薬剤および効果的なワクチン接種を含めた使用
JP2021142801A Pending JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Country Status (14)

Country Link
US (9) US10202426B2 (cg-RX-API-DMAC7.html)
EP (2) EP3174893B1 (cg-RX-API-DMAC7.html)
JP (3) JP6940916B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170031251A (cg-RX-API-DMAC7.html)
CN (2) CN107087411B (cg-RX-API-DMAC7.html)
AU (2) AU2015296555B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017001796A2 (cg-RX-API-DMAC7.html)
CA (2) CA2994218A1 (cg-RX-API-DMAC7.html)
EA (2) EA035372B1 (cg-RX-API-DMAC7.html)
ES (1) ES2816630T3 (cg-RX-API-DMAC7.html)
IL (2) IL250334B (cg-RX-API-DMAC7.html)
MX (2) MX385845B (cg-RX-API-DMAC7.html)
WO (2) WO2016019034A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701286B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3174893B1 (en) * 2014-07-30 2020-05-06 Genome Protection, Inc. Flagellin compositions and uses
JP6762030B2 (ja) 2014-11-20 2020-09-30 国立研究開発法人医薬基盤・健康・栄養研究所 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
KR20200031144A (ko) 2017-07-20 2020-03-23 스포겐 바이오테크 인코포레이티드 식물 보호, 성장 및 생산성 향상을 위한 생물활성 폴리펩타이드
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019094528A1 (en) * 2017-11-09 2019-05-16 The Scripps Research Institute An improved heroin vaccine
JP7037930B2 (ja) * 2017-12-19 2022-03-17 株式会社小糸製作所 車両の運転支援装置、命令表示装置及び車両用灯具。
CN109879940A (zh) * 2017-12-25 2019-06-14 苏州和锐生物科技有限公司 鞭毛g多肽、抗体捕获器件及试剂盒
AU2019261592A1 (en) * 2018-04-24 2020-11-19 Genome Protection, Inc. Methods for improving frailty and aging
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
EP3890769A4 (en) * 2018-12-07 2022-11-23 Genome Protection, Inc. COMPOSITIONS DERIVED FROM MODIFIED FLAGELLIN AND USES
CN111718417B (zh) * 2019-03-19 2022-10-14 宁波鲲鹏生物科技有限公司 含有荧光蛋白片段的融合蛋白及其用途
WO2020197296A1 (ko) * 2019-03-28 2020-10-01 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
CN110157655B (zh) * 2019-05-22 2021-06-01 中国兽医药品监察所 一种无毒性气肿疽梭菌基因工程亚单位疫苗用菌种及其应用
AU2020335893A1 (en) * 2019-08-30 2022-03-31 Genome Protection, Inc. Methods of increasing vaccine efficacy
IL312785A (en) 2020-05-19 2024-07-01 Cybin Irl Ltd Denatured Tryptamine Derivatives and Methods of Use
US20220389065A1 (en) * 2020-06-04 2022-12-08 The Catholic University Of Korea Industry-Academic Cooperation Foundation Anticancer composition comprising tlr5 agonist derived from flagellin as active ingredient
TWI746188B (zh) * 2020-09-28 2021-11-11 中山醫學大學 篩選治療腦炎藥物之平台及其方法
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
US20240277801A1 (en) * 2021-06-30 2024-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosol composition for pulmonary delivery of flagellin
KR102483177B1 (ko) * 2021-07-09 2022-12-29 전남대학교산학협력단 탈-면역 플라젤린 및 이를 포함하는 백신 조성물
KR102514849B1 (ko) * 2021-10-28 2023-03-28 전남대학교산학협력단 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물
KR20250029806A (ko) * 2022-06-01 2025-03-05 플래그 바이오, 인크. Rna 보조제, 이의 방법 및 용도
KR20240022417A (ko) * 2022-08-10 2024-02-20 주식회사 메디스팬 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도
WO2025172452A1 (en) * 2024-02-14 2025-08-21 Institut National de la Santé et de la Recherche Médicale Combination for treating bacterial infection due to pseudomonas aeruginosa antibiotic-resistant strain

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3007812A (en) 1957-02-11 1961-11-07 Allied Chem Water-repellent compositions, method of water-proofing porous surfaces therewith, and resulting water-repellent surfaces
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
JP3436756B2 (ja) * 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
WO1992005816A1 (de) 1990-09-28 1992-04-16 Gebrüder Sulzer Aktiengesellschaft Hohlnadel zur medizinischen verwendung und verfahren zur herstellung derartiger hohlnadeln
JP3368902B2 (ja) 1992-03-02 2003-01-20 カイロン エセ．ピー．アー． ワクチンおよび診断に有用なＨｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉタンパク質
US5693476A (en) 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
US20020009747A1 (en) 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
WO2001040280A2 (en) 1999-11-29 2001-06-07 Inotek Corporation Composition and method for treating a microbial infection
ATE360643T1 (de) 2000-01-31 2007-05-15 Munin Corp Humanes cyr61
US7300749B2 (en) 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2002216500A1 (en) 2000-11-28 2002-06-11 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
EP1379552B2 (en) 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-like receptor 5 ligands and methods of use
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
CA2462638A1 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7078165B2 (en) 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
WO2005056054A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
PL1706133T3 (pl) 2003-12-02 2011-04-29 Cleveland Clinic Found Sposoby ochrony przed promieniowaniem z użyciem flageliny
US7638485B2 (en) 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
US20050266391A1 (en) 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
WO2006039701A1 (en) 2004-10-01 2006-04-13 University Of South Florida Flagellin-based adjuvants and vaccines
CA2589556A1 (en) 2004-12-16 2006-08-03 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
WO2006069198A1 (en) 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
EP1940419A2 (en) 2005-09-09 2008-07-09 Oregon Health and Science University Neuroprotectants
US20070269406A1 (en) 2005-12-14 2007-11-22 Ichim Thomas E Transcatheter tumor immunoembolization
EP2441846A3 (en) 2006-01-09 2012-07-25 The Regents Of the University of California Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy
EP2114427B1 (en) 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
JP2010530005A (ja) 2007-06-15 2010-09-02 イミュアールエックス・インコーポレーテッド Ｔｎｆ−ｒアゴニスト療法レジメンの毒性を緩和するためのｔｌｒアゴニスト及び／又は１型インターフェロンの使用
KR20100063048A (ko) 2007-07-31 2010-06-10 더 존스 홉킨스 유니버시티 신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체
CA2704583A1 (en) 2007-11-07 2009-05-14 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 receptor(dec-205)
WO2009102818A1 (en) 2008-02-11 2009-08-20 Cleveland Biolabs, Inc. Method for reducing the effects of chemotheraphy using flagellin related polypeptides
PT2320948E (pt) * 2008-08-01 2013-06-17 Cleveland Clinic Foundation Métodos para o tratamento de lesões por reperfusão
EP2349291B1 (en) * 2008-10-03 2012-12-05 Emory University Agonists of toll-like receptor 5 for the treatment of graft-versus-host disease
JP5913093B2 (ja) 2009-05-21 2016-04-27 アストラゼネカ アクチボラグ 新規ピリミジン誘導体と、癌とさらなる疾患の治療におけるそれらの使用
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
CA2777198C (en) 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
EP2547362B1 (en) * 2010-03-17 2021-08-25 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
US9683020B2 (en) * 2011-08-01 2017-06-20 Emory University VLPS containing ligands and methods related thereto
CN102965386A (zh) * 2011-09-02 2013-03-13 中国人民解放军军事医学科学院放射与辐射医学研究所 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法
CN102772795B (zh) * 2012-08-06 2015-07-29 中国人民解放军疾病预防控制所 布鲁氏菌鞭毛蛋白bmeii1112在制备布鲁氏菌亚单位疫苗中的应用
EP3174893B1 (en) * 2014-07-30 2020-05-06 Genome Protection, Inc. Flagellin compositions and uses

Also Published As

Publication number Publication date
IL250334B (en) 2021-09-30
US11542306B2 (en) 2023-01-03
EP3174552A1 (en) 2017-06-07
US20190233478A1 (en) 2019-08-01
CA2994289C (en) 2023-03-14
EP3174893A4 (en) 2018-01-03
US20210269491A1 (en) 2021-09-02
CN107087411A (zh) 2017-08-22
BR112017001796A2 (pt) 2018-02-14
AU2015296298A8 (en) 2017-03-23
IL250334A0 (en) 2017-03-30
AU2015296555A1 (en) 2017-02-23
CN107087411B (zh) 2021-06-29
US10336793B2 (en) 2019-07-02
US11034733B2 (en) 2021-06-15
US10975127B2 (en) 2021-04-13
US20180251498A1 (en) 2018-09-06
AU2015296298A1 (en) 2017-03-16
EA201790273A1 (ru) 2017-07-31
EA201790294A1 (ru) 2017-08-31
CN107073092A (zh) 2017-08-18
CA2994289A1 (en) 2016-02-04
US20170266278A1 (en) 2017-09-21
EP3174893A1 (en) 2017-06-07
IL250331A0 (en) 2017-03-30
WO2016019034A1 (en) 2016-02-04
US20200277339A1 (en) 2020-09-03
AU2015296298B2 (en) 2020-05-21
US20190315810A1 (en) 2019-10-17
US10669316B2 (en) 2020-06-02
KR20170031251A (ko) 2017-03-20
MX2017001279A (es) 2017-08-07
JP6646039B2 (ja) 2020-02-14
JP2017523184A (ja) 2017-08-17
EA037407B1 (ru) 2021-03-25
JP2017523180A (ja) 2017-08-17
MX385845B (es) 2025-03-18
US10202426B2 (en) 2019-02-12
EP3174893B1 (en) 2020-05-06
US10730915B2 (en) 2020-08-04
EP3174552B1 (en) 2020-09-16
US20180354995A1 (en) 2018-12-13
WO2016019134A1 (en) 2016-02-04
CA2994218A1 (en) 2016-02-04
EA035372B1 (ru) 2020-06-03
MX2017001406A (es) 2017-08-28
EP3174552A4 (en) 2018-02-28
IL250331B (en) 2021-06-30
US20210340190A1 (en) 2021-11-04
AU2015296555B2 (en) 2020-05-21
JP2021191781A (ja) 2021-12-16
US20200392190A1 (en) 2020-12-17
ES2816630T3 (es) 2021-04-05
ZA201701286B (en) 2018-04-25
WO2016019134A8 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
JP6940916B2 (ja) フラジェリン組成物および使用
WO2018187740A1 (en) Bioorthogonal compositions
US20230310558A1 (en) Alkaline phosphatase agents for treatment of radiation disorders
JP2022523740A (ja) Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療
US20220024991A1 (en) Engineered flagellin-derived compositions and uses
EP4281116A1 (en) Bone-specific delivery of polypeptides
WO2016014899A1 (en) Flagellin derivatives and uses
US20240226306A1 (en) Trem-2/dap-12 inhibitors for treating lung disease and injury and combinations thereof
HK1237803B (en) Flagellin compositions and uses
HK1237803A1 (en) Flagellin compositions and uses
Astuti et al. Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis.
WO2024246203A1 (en) Anti-cd2 single domain antibody, a pharmaceutical composition and a kit for use in the diagnosis and/or therapy of cancer
WO2020232638A1 (zh) 一种抗体偶联物及其药物组合物的应用
TW202537643A (zh) 抗體-藥物結合物之用途
CN108096258A (zh) 环磷酰胺与表柔比星联合用途及其检测设备
Lucio et al. P-167 Transbronchial needle aspiration (TBNA): Results in evaluating patients with mediastinal-hilar disease
Maniate et al. P-168 Outcome of lung cancer patients admitted to intensive care unit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180727

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201113

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210803

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210901

R150 Certificate of patent or registration of utility model

Ref document number: 6940916

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees